The phase III ToGA enrolled 594 patients with HER2 overexpressed advanced GC in 24 countries including Europe, Central America, South America, and Asia; patients were assigned in a 1:1 ratio to either trastuzumab in combination with chemotherapy (capecitabine or 5-FU plus cisplatin, n = 298) or chemotherapy alone (n = 296) [13]. The gene discussed is ERBB2; the disease is gastric cancer.